Compare SNDA & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDA | ZLAB |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1997 | 2017 |
| Metric | SNDA | ZLAB |
|---|---|---|
| Price | $41.05 | $18.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $35.75 | ★ $49.60 |
| AVG Volume (30 Days) | 479.6K | ★ 714.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | $381,141,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $68.73 | $9.75 |
| Revenue Next Year | $11.11 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | 15.33 |
| 52 Week Low | $23.78 | $15.96 |
| 52 Week High | $44.39 | $39.64 |
| Indicator | SNDA | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 39.86 |
| Support Level | $30.78 | $16.84 |
| Resistance Level | $42.79 | $19.55 |
| Average True Range (ATR) | 1.62 | 0.76 |
| MACD | 0.07 | -0.25 |
| Stochastic Oscillator | 60.44 | 4.64 |
Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic services offered by the company at its senior housing communities comprise meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.